Biogen Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2017. For the quarter, the company reported total revenue of $3,307.0 million against $2,872.0 million a year ago. Income from operations was $1,465.8 million against $886.2 million a year ago. Income before income tax expense and equity in loss of investee, net of tax was $1,399.8 million against $838.2 million a year ago. Net loss attributable to company was $297.4 million or $1.40 per diluted share against income of $649.2 million or $2.99 per diluted share a year ago. Non-GAAP earnings per share - diluted were $5.26 against $5.04 a year ago. Non-GAAP net income attributable to was $1,116.1 million against $1,093.2 million a year ago.

For the full year, the company reported total revenue of $12,273.9 million against $11,448.8 million a year ago. Income from operations was $5,344.2 million against $5,150.4 million a year ago. Income before income tax expense and equity in loss of investee, net of tax was $5,128.8 million against $4,933.0 million a year ago. Net income attributable to company was $2,539.1 million or $11.92 per diluted share against $3,702.8 million or $16.93 per diluted share a year ago. Non-GAAP earnings per share - diluted were $21.81 against $20.22 a year ago. Non-GAAP net income attributable to was $4,645.4 million against $4,422.7 million a year ago.
The company provided earnings guidance for the full year 2018. Revenue is expected to be approximately $12.7 billion to $13.0 billion. GAAP tax rate is expected to be approximately 23.5% to 24.5%; non-GAAP tax rate is expected to be approximately 22.5% to 23.5%. GAAP diluted EPS is expected to be between $22.20 and $23.20. Non-GAAP diluted EPS is expected to be between $24.20 and $25.20. GAAP net income attributable to the company is expected to be $4,812 million. Non-GAAP net income attributable to the company is expected to be $5,237 million.